Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
September 23 2022 - 8:50AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it will present preclinical
data on the potency of Lantern’s drug candidate LP-284 for mantle
cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at
the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting,
Sept. 28 – Oct. 1, 2022, in Houston, TX.
LP-284 is a next generation acylfulvene that has a synthetically
lethal mechanism of action in cancers with impaired DNA damage
repair (DDR) pathway genes. In Lantern’s preclinical testing,
LP-284 has shown in vitro and in vivo anti-tumor potency across a
range of non-Hodgkin’s B-cell lymphomas. Of the lymphomas tested to
date, LP-284 had the greatest potency against numerous MCL cell
lines, including those that are resistant to the standard-of-care
(SOC) agents Ibrutinib and Bortezomib. In the US, MCL is estimated
to be diagnosed in around 4,500 patients each year and represents
an approximate $200 million in annual therapy sales.
Lantern’s LP-284 program has been accelerated and de-risked
using A.I. insights and biological modeling powered by RADR®.
Lantern has been able to advance LP-284 from initial RADR® insights
regarding anti-cancer activity and potential mechanisms of action
in hematological cancers, to selection of specific subtypes of
lymphomas with superior response, to late stage IND enabling
studies and initial design of first in human clinical trials in
less than 2 years. Lantern is planning on an IND submission for
LP-284 in Q1 2023 and anticipates launching a Phase 1 clinical
trial in Q2 2023.
Details of the poster presentation are listed below and can be
found on the SOHO website. A full version of the poster will be
available on Lantern’s website on October 3, 2022.
Title: LP-284 - A Highly Potent Small Molecule Targeting
Mantle Cell Lymphoma Date and Time: September 28, 2022,
5:05pm CT Poster Number: MCL-319 Presenter: Jianli
Zhou, Lantern Pharma
About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine learning platform
to discover biomarker signatures that identify patients most likely
to respond to its pipeline of genomically-targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across nine disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Forward-looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; expectations and estimates regarding
clinical trial timing and patient enrollment; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding patient
populations, potential markets and potential market sizes; sales
estimates for our drug candidates and our plans to discover and
develop drug candidates and to maximize their commercial potential
by advancing such drug candidates ourselves or in collaboration
with others. Any statements that are not statements of historical
fact (including, without limitation, statements that use words such
as "anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "objective," "aim," "upcoming,"
"should," "will," "would," or the negative of these words or other
similar expressions) should be considered forward-looking
statements. There are a number of important factors that could
cause our actual results to differ materially from those indicated
by the forward-looking statements, such as (i) the impact of the
COVID-19 pandemic, (ii) the risk that our research and the research
of our collaborators may not be successful, (iii) the risk that
none of our product candidates has received FDA marketing approval,
and we may not be able to successfully initiate, conduct, or
conclude clinical testing for or obtain marketing approval for our
product candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220923005075/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024